-
Genetic characteristics of microglia in Alzheimer's disease revealed
Time of Update: 2021-05-31
They studied the differences in gene expression behind the ability of microglia to take up particles (such as amyloid plaques) and identified related regulatory molecules.
-
Health Commission: 16 new confirmed cases and 2 local cases
Time of Update: 2021-05-31
As of 24:00 on May 28, according to reports from 31 provinces (autonomous regions and municipalities) and the Xinjiang Production and Construction Corps, there are currently 318 confirmed cases (including 4 severe cases), 86,107 cured and discharged cases, and 4,636 deaths.
-
PI3K dual inhibitor!
Time of Update: 2021-05-23
's Duensibu Capsules (trade name: Kebituo) has been approved by the China National Medical Products Administration ( NMPA) accepted and received conditional approval for listing and priority review qualifications.
Reference materials:[1]Voluntary Announcement-The National Medical Products Administration accepts the listing application of "Duensibu Capsules".
-
Amgen 2021Q1: Strong growth of biosimilars, AMG510 approval results will soon be announced
Time of Update: 2021-05-23
Although sales of Enbrel (etanercept), an autoimmune disease treatment drug for rheumatoid arthritis, fell 20% from the first quarter of last year, it was still Amgen’s highest-revenue product, reaching US$924 million.
-
Pioneer Pharmaceuticals completes the first patient administration in the treatment of COVID-19 in the U.S. Phase III clinical trial with procrulamide
Time of Update: 2021-05-23
On the 25th, the pioneering pharmaceutical industry announced that the Phase III clinical trial of Prokalamide for the treatment of male patients with mild and moderate new coronary disease approved by the US FDA has completed the enrollment and administration of the first subject in a clinical center in the US.
-
Novartis Q1: Entresto submits US$789 million US listing application for tislelizumab at the end of the year
Time of Update: 2021-05-23
Sales in the Chinese market reached US$744 million, an increase of 11%.
Novartis' current business is divided into two main lines: innovative drugs and generic drugs.
In the first quarter, net sales of innovative drugs were US$10.
-
Top 10 drugs in advertising expenditures in the biopharmaceutical sector in 2020
Time of Update: 2021-05-23
According to Kantar's monitoring data, AbbVie's advertising spending on Humira has reached billions of dollars in the past eight years.
In terms of two indications of atopic dermatitis and asthma, advertising expenditure in 2020 reached 409 million US dollars.
-
Up to 92% drop in consumables selection results announced: Johnson & Johnson, Xerox Hui, Telif...
Time of Update: 2021-05-23
On April 24, the Suzhou Municipal Medical Insurance Bureau issued the "Announcement on the Results of the Negotiations for the Su Yansu Xutonghuai Public Medical Institutions' Medical Consumables Alliance to Bring Volume Renewal and Expansion", showing:The companies to be selected for synthetic bones include Nade, Tianjin Saining Biotechnology, etc.
-
Successfully promote hair regrowth! Eli Lilly's JAK inhibitor is expected to submit a regulatory application this year
Time of Update: 2021-05-23
But don't be afraid, the dawn of hope is about to shine on the exposed scalp!Today, Eli Lilly and Incyte announced that their JAK inhibitor baricitinib has achieved positive results in the second phase 3 clinical trial BRAVE-AA1 for the treatment of patients with severe alopecia areata.
-
AstraZeneca Selumetinib and Tagrisso are recommended and approved by the EU
Time of Update: 2021-05-23
On the same day, AstraZeneca also announced that Tagrisso (osimertinib) has also been recommended for marketing in the European Union for the adjuvant treatment of early (IB, II and IIIA) epidermal growth factor receptor mutations (EGFRm) non-small cell lung cancer (NSCLC) adults Patients, these patients still have treatment intentions after the tumor is completely removed.
-
Roche's new anti-influenza drug Xofluza will soon be approved in China
Time of Update: 2021-05-23
On April 25, the official website of NMPA showed that the review status of Roche’s new anti-influenza drug Mabaloxavir Tablets (Xofluza) (acceptance number JXHS2000074/75) was changed to "under approval", which means that this new mechanism of action Innovative anti-influenza drugs are not far from being launched in China.
-
The clinical application of Tonghua Dongbao subsidiary's three-target inhibitor product was accepted
Time of Update: 2021-05-23
("Dongbao Zixing") declared a three-target inhibitor (THDBH101 capsule/WXSHC071 capsule) ) (Acceptance number CXHL2101065 country, CXHL2101066 country, CXHL2101067 country) drug registration application, recently received the clinical application acceptance notice issued by the State Drug Administration.
-
Sansheng Guojian Recombinant Anti-IL-17A Humanized Monoclonal Antibody Phase II Clinical Completion of the First Subject Enrolled
Time of Update: 2021-05-23
In the completed phase I clinical trial of healthy adult volunteers with a single dose and escalating dose, 608 showed good tolerability and safety.
-
Unable to pay off the debts due, a bank filed with the court for bankruptcy and reorganization of Kangmei
Time of Update: 2021-05-23
(hereinafter referred to as "Jiedong Rural Commercial Bank") filed a bankruptcy reorganization with the court because Kangmei was unable to pay off its due debts.
Up to now, the company has not repaid Jiedong Rural Commercial Bank's loan principal of 49 million yuan and interest of 505,730.
-
Innovating the first-line treatment pattern for gastric cancer BMS, Merck, Baekje and other companies are developing in China
Time of Update: 2021-05-23
Data show that in the Chinese population, compared with chemotherapy alone, Opdivo combined with chemotherapy as the first-line treatment for unresectable advanced or metastatic gastric cancer and gastroesophageal junction cancer has achieved clinically significant overall survival (OS) and progression-free survival Period (PFS) benefit.
-
Johnson & Johnson's new indication for daratumumab is about to be approved in China
Time of Update: 2021-05-23
Although many progresses have been made in the treatment of multiple myeloma in recent years, most patients still face the problem of relapse or drug resistance.
-
FDA review storm results are here!
Time of Update: 2021-05-22
Based on the clinical trial results of IMvigor210, the FDA has accelerated the approval of Tencentriq for the treatment of locally advanced or Patients with metastatic urothelial carcinoma, but the subsequent clinical study of IMvigor130 showed that although Tencentriq combined with chemotherapy has obvious advantages in progression-free survival, the advantages in overall survival are still insufficient.
-
Luye Pharmaceutical's innovative compound liposome formulation completes the first patient enrollment in Phase I clinical trials
Time of Update: 2021-05-22
On April 29, Luye Pharmaceutical Group announced that its self-developed innovative anti-tumor preparation-Irinotecan Hydrochloride Liposome Injection (LY01616) has completed the first phase I clinica
-
Two departments request to speed up the direct settlement of outpatient expenses across provinces
Time of Update: 2021-05-22
" The notice requires that by the end of 2021, more than 60% of the counties in all provinces have at least one inter-provincial networked medical institution for general outpatient expenses, and the overall planning area basically realizes direct settlement of ordinary outpatient expenses across provinces.
-
Development of farnesol receptor agonist LJN452: application examples of conformational restriction strategies
Time of Update: 2021-05-22
The compound has excellent performance in in vitro testing, but the PK data is too poor (high clearance and low bioavailability), as well as potential toxicity and light instability, mainly caused by the stilbene structure in the structure, which greatly limits the possibility of its preparation as a drug Therefore, the optimization of the stilbene structure has become the first breakthrough direction.
